

1 **Additional file 2. Unadjusted and adjusted hazard ratios of treatment switching**  
 2 **(n= 6269).**

3

	Univariate analysis			Multivariate analysis		
	cHR*	95% CI	p	aHR**	95% CI	p
<b>VL group</b>						
6 months	1		0.803	1		0.008
3 months	1.02	0.85-1.23		0.73	0.58-0.92	
<b>Sex</b>						
Female	1		0.006	1		0.150
Male	0.75	0.60-0.92		0.85	0.67-1.06	
<b>Age<sup>1</sup></b>						
16-24	1		<0.001	1		<0.001
25-34	0.49	0.39-0.62		0.48	0.38-0.62	
35-44	0.38	0.29-0.50		0.38	0.28-0.51	
45-60	0.31	0.21-0.48		0.34	0.22-0.52	
<b>CD4 count<sup>2</sup></b>	0.84	0.78-0.90	<0.001	0.85	0.79-0.91	<0.001
<b>WHO stage</b>						
I + II	1		0.004	1		0.001
III + IV	1.48	1.13-1.94		1.69	1.24-2.29	
<b>Clinic</b>						
I	1		<0.001	1		0.005
II	0.76	0.61-0.94		0.72	0.57-0.90	
III	0.48	0.38-0.59		0.46	0.37-0.58	
<b>Baseline NNRTI</b>						
Nevirapine	1		0.089	1		0.008

Efavirenz	0.86	0.71-1.02		0.76	0.63-0.93	
<b>ART initiation<sup>3</sup></b>	0.97	0.96-0.99	0.001	0.97	0.95-0.99	0.009

4

5 \* cHR, crude hazard ratio

6 \*\* aHR, adjusted hazard ratio

7 \*\*\* PHA, p value for the global proportional-hazards assumption; VIF, range of

8 variance inflation factors

9 <sup>1</sup> The variable age was categorized because the proportional-hazards assumption (PHA)  
10 was violated.

11 <sup>2</sup> per 50 cells/ $\mu$ l

12 <sup>3</sup> Calendar time of ART initiation; per 90 days